Sanofi India Q2 2026: Diabetes strength and cost discipline lift quarterly profits

Sanofi India used the June 2026 quarter to underline what its leadership has been saying since last year’s strategic reset. The growth engine is diabetes, the profitability lever is operating discipline, and the near-term swing factors are partnerships and exports.

For Q2 2026, the company reported total income of INR 443.9 crore, up 7% year on year, with sales contributing 94% of the mix. Within domestic sales, momentum was clearly led by the insulin franchise, supported by a sharper push into public sector accounts and a steady contribution from partnerships.

The quarter also showed visible improvement in profitability. Profit before tax and exceptional items rose 19% year on year and the profit ratio improved to 27% of net sales from 24% last year. Management attributed the improvement to strong execution in the diabetes business, a continued return on investment from partnerships, and tighter operating expense control.

A quarter where diabetes did the heavy lifting

Domestic sales for Q2 2026 were INR 355.9 crore, up 8% year on year. The domestic mix tilted further toward insulins, which reached INR 203.1 crore and formed 57% of domestic sales. Partnerships contributed INR 145.7 crore or 41%, while other domestic sales were INR 7.1 crore.

Management’s narrative for the diabetes business was consistent across the presentation and the call. The company positioned itself as the basal insulin market leader and highlighted continued portfolio momentum driven by Toujeo and Soliqua. A key execution lever was the public sector. Management stated that public sector acceleration was 70%, driven by opening new accounts for Toujeo and Soliqua in CARE and state accounts.

The investor interaction added more color to the strategy behind the quarter. The company reiterated its diabetes playbook as a combination of market leadership, innovation, and access expansion. Alongside commercial execution, Sanofi India also emphasized building real-world evidence, citing the LANDMARC RWE study and multiple Toujeo and Soliqua publications aimed at strengthening positioning with Indian datasets.

Costs moved in the right direction, and it showed in margins

The cost story in Q2 was not about large cuts, but about consistent discipline. Employee costs were broadly stable, while other operating expenses reduced. Total operating expenses excluding depreciation and finance costs were INR 97.2 crore in Q2 2026 versus INR 102.7 crore in Q2 2025.

This discipline mattered because it supported margin expansion in a quarter when management wanted to show that growth and profitability can move together. Profit before tax and exceptional items improved from INR 94.1 crore to INR 112.3 crore, and PBT as a percent of net sales increased from 24% to 27%.

Management framed this as part of a broader operating model transformation that was completed last year. The stated focus is now on insulin and a partnership model for selected legacy brands, combined with what the company called operational excellence.

H1 2026: Q2 offset a weak start, but the first half remained under pressure

While the quarter was strong, the first half of the year was more muted. Total income year to date June 2026 was INR 920.6 crore, down 4% year on year. Sales were down 2% and other operating income also declined, which management linked largely to services and the consumer health related services that were provided in the past and are no longer provided.

On sales, the company noted that diabetes grew strongly in H1, but overall domestic sales were down 2% due to what management called a one-off in 2025 and a transition impact in partnerships. In the Q&A, investors pressed the management on the partnership segment, pointing out that growth was only 2% in Q2 and did not appear to match broader market growth in cardio and CNS.

The CFO explained that the partnership structure includes primary sales to partners and that prior-year safety stock build and certain transition arrangements created distortions, particularly in Q1. For Q2, management acknowledged growth was below expectations and said the company is working with partners through a steering committee, including partner reorganization and reinvestment behind the portfolio. The Managing Director added that partnership performance differs across sub-areas and cited better alignment in oral anti-diabetics, including the Amaryl partnership.

Exports were another source of pressure. Export sales were down 2% in Q2, and management spoke about challenges in Australia due to heavy competition for mature products. The export strategy described on the call focused on offsetting losses in Australia by scaling other markets such as France, Italy, Turkey, and Russia, pursuing tenders such as South Africa, specializing the Goa site for certain products, and bringing outsourced products back from CMOs to increase manufacturing volume.

Competitive landscape and the next phase of execution

A key investor question was about competitive intensity in basal insulin, including innovation like once-weekly insulin. Management welcomed innovation and positioned the market as having distinct patient profiles, arguing that once-weekly and once-daily options may serve different needs. The company’s emphasis remained on expanding access, especially in public sector channels such as CGHS, ESI, Railways, state, and defense-related accounts, and on continuing digital outreach in Tier II and Tier III markets.

The second thread was technology enablement. Management referred to internal AI readiness initiatives and spoke about exploring devices and AI platforms that can support patient support programs and simplify insulin initiation and intensification. These were described as evaluations and business cases rather than committed launches, but they provide a sense of where incremental investment and capability building may occur.

On capital return, the CFO stated that the company’s cash position increased 34% and described the balance sheet as healthy. On dividends, he indicated an expectation of maintaining at least last year’s payout level, subject to board decision, while explicitly avoiding a firm forward-looking commitment. On buybacks, he stated that such proposals are discussed at the board level but are not part of the current strategy.

Takeaways for investors

Sanofi India’s June 2026 quarter was a clear demonstration of the company’s current playbook. Diabetes growth, boosted by public sector wins for Toujeo and Soliqua, was the primary driver of domestic performance. Cost discipline supported a meaningful improvement in quarterly profitability.

At the same time, the documents show why investors remain focused on the other moving parts. Partnerships are strategically important but currently not growing at the pace the market would expect, and exports remain exposed to competitive pressure in mature markets such as Australia. The company’s ability to stabilize these areas while sustaining diabetes momentum will determine whether the Q2 margin improvement becomes a durable trend rather than a single-quarter highlight.